UnitedHealth says 'too early to speculate' on outcome of healthcare reform
Expects performance momentum to carry forward for balance of year into 2018 and beyond. Says entering 2H17 "in a strong position." Says expects to increase overall Medicare Advantage market share in 2018. Says Optum segments grew revenues by double digit percentage points in Q2. Says OptumRx revenue yield was flat as "we effectively passed on supply chain improvement to our customers." Says pricing "disciplined" and "rational." Says SCA unit performance "slightly ahead of expectations." Expects cash flows from operations of approximately $12B for FY17, an increase of 22.5% over 2016. Says headwinds to 2018 earnings include national, state healthcare policies, funding trends. Says respects complexity of political and social issues of national healthcare reform, too early to speculate on outcome.